Dear all
Further to my post a couple of months ago about work in progress to create personalised vaccine for patients with certain types of B-cell lymphomas (including WM), there has been a further development towards this being a possibility in Europe (see link below). It is still early days, but WM patients will be looking out for further news with great interest.
www.businesswire.com/news/home/20120119005...
Biovest today announced that the European Medicines Agency (EMA) has granted Small and Medium Sized Enterprise (SME) status to Biovest. With EMA SME status confirmed, Biovest will be provided with certain administrative and economic benefits related to the EU regulatory process for the Companys BiovaxID® personalized lymphoma vaccine targeting the treatment of certain B-cell subtypes of non-Hodgkins lymphoma.
Best wishes,
Phil
--
Phil Manning, English language moderator